Investing Profile

Andrew Levin

VC
Photo of Andrew Levin, Managing Partner at RA Capital

Signal uses Gmail to reveal intro paths. Email content is never read.

Sign in with Google →
cb
RA Capital Managing Partner
14
CompanyStageDateRound SizeTotal Raised
Superluminal Medicines
SeedAug 2023$33M
$33M
Lusaris Therapeutics
Series ANov 2022$60M
$60M
Metagenomi
Series BJan 2022$180M
Series ANov 2020$75M
$280M
Co-investors: Sebastian Bernales (Humboldt Fund), Victor Wang (HOF Capital), Kyle Kurpinski (Tencent Holdings), Jeremy Yap
Expansion Therapeutics
Series BSep 2021$80M
Series AJan 2018$55M
$140M
Co-investors: Scott Rocklage (5am Ventures), Beth Seidenberg (Westlake Village BioPartners)
Delix Therapeutics
Series ASep 2021$70M
$70M
Co-investors: Ken Belotsky (Negev Capital), Matias Serebrinsky (PsyMed Ventures), Vasudev Bailey (Artis Ventures (AV))
Eliem Therapeutics
Series BMay 2021$60M
Series AMar 2021$80M
$140M
Co-investors: Liam Ratcliffe (Access Biotechnology)
Alchemab Therapeutics
Series AApr 2021$83M
$83M
Co-investors: Houman Ashrafian (SV Health Investors)
Synthorx
Series CApr 2018$63M
Series BJul 2016$10M
$73M
Co-investors: Peter Thompson (OrbiMed)